Medtronic (MDT) is reshaping its business with plans to spin off its Diabetes segment through a MiniMed Group IPO, while advancing its Stealth AXiS spine surgery platform, moves that directly affect how investors may view the stock.

Despite a recent soft patch, with a 30 day share price return of 3.99% decline and a 90 day share price return of 7.97% decline, Medtronic’s 1 year total shareholder return of 10.07% and 3 year total shareholder return of 29.86% suggest longer term holders have still seen gains as the market weighs the MiniMed IPO, Stealth AXiS approval, and ongoing guidance.

If Medtronic’s moves in diabetes tech and surgical robotics have your attention, it could be a good moment to size up 30 healthcare AI stocks as potential next ideas on your list.

With Medtronic shares slipping over 30 and 90 days but still showing gains over 1 and 3 years, and trading at a discount to the average analyst price target, is this weakness a reset or is the market already pricing in future growth?

Most Popular Narrative: 1.7% Overvalued

Medtronic’s last close at $96.65 sits slightly above the fair value of $95.00 in the most followed valuation narrative, which frames the recent pullback as less dramatic than the headlines might suggest.

Strengths and Competitive Advantages: Diverse Product Portfolio: Medtronic operates across four key segments: Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes. This provides revenue stability and reduces dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics). Robust R&D and Innovation: With an annual R&D investment of approximately $2.7 billion (9% of revenue), Medtronic maintains a strong pipeline, including developments such as the Hugo robotic-assisted surgery system (competing with Intuitive Surgical’s da Vinci) and the MiniMed 780G insulin pump. Recent FDA approvals, such as the PulseSelect AF ablation system, reflect continued innovation momentum.

Curious how a diversified device portfolio and heavy R&D spending still land just a shade above fair value. The key assumptions blend steady top line growth, firm margins, and a future earnings multiple usually linked with higher growth names. Want to see exactly how those ingredients come together in the narrative’s pricing playbook.

Result: Fair Value of $95.00 (OVERVALUED)

However, you still need to watch for regulatory setbacks or product recalls, as well as any further weakness in the Diabetes unit that could undercut the current fair value story.

Another View: Earnings Multiple Sends a Different Signal

The 1.7% premium to the $95.00 fair value in the most followed narrative looks modest, but the current P/E of 26.9x tells a slightly different story. It sits below peers at 44.1x, below the US Medical Equipment industry at 30.4x, and below a fair ratio of 36.1x that the market could move towards over time.

For some investors, that spread may look like a valuation cushion. For others, it may look like a warning that expectations for growth and returns are capped. Which narrative feels closer to how you see Medtronic’s future?

Next Steps

If this mix of optimism and caution around Medtronic leaves you on the fence, take a moment to review the data yourself and decide where you stand. You can start with 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Medtronic has sharpened your focus, do not stop here. Widening your watchlist with targeted screens can reveal opportunities you would otherwise overlook.

• Hunt for mispriced quality by checking our 53 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect them yet.
• Build a steadier income base by reviewing 15 dividend fortresses that aim to combine higher yields with more durable payout profiles.
• Prioritise resilience by scanning 80 resilient stocks with low risk scores where balance sheets and risk scores help you focus on stability first.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.